Stifel Nicolaus Forecasts Strong Price Appreciation for Enliven Therapeutics (NASDAQ:ELVN) Stock

Enliven Therapeutics (NASDAQ:ELVN) had its target price hoisted by equities researchers at Stifel Nicolaus from $60.00 to $80.00 in a research note issued on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price indicates a potential upside of 58.98% from the stock’s previous close.

A number of other equities research analysts have also weighed in on ELVN. Guggenheim initiated coverage on shares of Enliven Therapeutics in a report on Tuesday, May 12th. They set a “buy” rating and a $80.00 target price on the stock. Wall Street Zen raised shares of Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Monday, May 11th. Mizuho lifted their price target on shares of Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Monday, April 20th. Finally, JonesTrading upped their price target on Enliven Therapeutics from $45.00 to $70.00 and gave the company a “buy” rating in a research report on Monday. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $67.83.

Enliven Therapeutics Price Performance

ELVN stock traded down $0.43 during midday trading on Wednesday, reaching $50.32. 65,736 shares of the stock were exchanged, compared to its average volume of 1,333,895. Enliven Therapeutics has a 52 week low of $14.78 and a 52 week high of $52.39. The company has a fifty day moving average price of $42.34 and a 200 day moving average price of $32.98. The stock has a market capitalization of $3.06 billion, a PE ratio of -30.22 and a beta of 0.29.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.44) by $0.06. As a group, analysts anticipate that Enliven Therapeutics will post -1.71 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $34.54, for a total transaction of $345,400.00. Following the sale, the director owned 51,884 shares of the company’s stock, valued at approximately $1,792,073.36. This represents a 16.16% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the transaction, the chief financial officer directly owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. This trade represents a 10.55% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 3.00% of the company’s stock.

Hedge Funds Weigh In On Enliven Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. KBC Group NV acquired a new position in shares of Enliven Therapeutics during the 1st quarter valued at $38,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock worth $44,000 after purchasing an additional 594 shares during the period. BNP Paribas Financial Markets grew its holdings in Enliven Therapeutics by 33.3% in the second quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares during the period. Los Angeles Capital Management LLC bought a new stake in Enliven Therapeutics in the fourth quarter valued at $83,000. Finally, Quantbot Technologies LP increased its stake in Enliven Therapeutics by 47.1% in the second quarter. Quantbot Technologies LP now owns 4,477 shares of the company’s stock valued at $90,000 after purchasing an additional 1,434 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.